CTNNB1 and neoplasm: While several activating mechanism have been identified (i.e. loss of expression of extracellular inhibitors), we propose that chondroitin sulfate in the tumor microenvironment, including CS-E, participates in this complex regulatory network of the Wnt/beta-catenin pathway.